European Journal of Rheumatology is a premier, peer-reviewed journal that has been paving the way for innovative research and in-depth analysis in the field of rheumatology since its launch. Published by AVES, this Open Access journal has been accessible to researchers, professionals, and students worldwide since 2014, promoting the sharing of valuable knowledge on rheumatic diseases and their treatment. With an ISSN of 2147-9720 and an E-ISSN of 2148-4279, it provides a prominent platform for groundbreaking studies and clinical evaluations that bridge scientific discovery with practical application. The journal’s mission is to enhance the understanding of rheumatological conditions and facilitate advancements in therapeutic strategies, making it an essential resource for anyone devoted to the improvement of patient care in this dynamic field. The European Journal of Rheumatology is committed to upholding the highest standards of scholarly publishing and aims to foster collaboration among researchers and practitioners across Europe and beyond.

Reumatismo is a distinguished Open Access journal dedicated to the field of rheumatology, published by PAGEPRESS PUBL since 2001. With a rich history dating back to 1952, this journal has been pivotal in disseminating vital research on rheumatic diseases and related disorders. Based in Italy, Reumatismo has earned a reputation for its quality and relevance, achieving a Q3 category ranking in the 2023 Scopus metrics for Rheumatology, reflecting its significant contributions to the field. The journal is committed to providing a platform for the latest scientific developments and clinical innovations, thus aiding researchers, healthcare professionals, and students striving to enhance understanding and treatment of rheumatic conditions. For those seeking to access comprehensive research articles and studies, Reumatismo boasts an open access policy, ensuring that knowledge is freely available to all, fostering collaboration and advancement in rheumatology worldwide.

Dermatologie, published by SPRINGER HEIDELBERG, is a prominent journal dedicated to the advancing field of dermatology. With its ISSN 2731-7005 and E-ISSN 2731-7013, this journal has established itself as a valuable resource for researchers, professionals, and students alike. Originating in Germany, the journal focuses on disseminating innovative research from 2022 to 2024, contributing significantly to the understanding of skin health and disease management. Despite its current ranking within the Q3 category in dermatology and a Scopus rank of #88/142, it provides critical insights and advances in clinical practice, epidemiology, and therapeutic modalities. With an emphasis on open discourse, it seeks to foster collaboration among healthcare professionals and researchers, thereby enhancing the quality and accessibility of dermatological research. Engage with Dermatologie to stay at the forefront of the latest advancements in skin-related health issues.

The Scandinavian Journal of Rheumatology, published by Taylor & Francis Ltd, is a prestigious peer-reviewed journal dedicated to advancing research in the fields of rheumatology, immunology, and related disciplines. With an ISSN of 0300-9742 and an E-ISSN of 1502-7732, this journal has established itself as a vital platform for disseminating significant findings and innovative approaches in the management of rheumatic diseases since its inception in 1959. As a recognized scholarly outlet, it currently resides within the Q2 category for Medicine (miscellaneous) and ranks #39 out of 73 in Rheumatology according to the 2023 Scopus assessments. This reflects the journal's commitment to high-quality research and its relevance in the scientific community. Although it does not provide Open Access options, the journal's rigorous selection process ensures that only the most impactful research reaches its audience, making it a crucial resource for researchers, clinicians, and students engaged in the exploration of rheumatological and immunological challenges. The journal's broad scope encompasses ongoing studies, clinical trials, and reviews that aim to enhance understanding and treatment of rheumatic conditions, promoting collaboration and knowledge-sharing among professionals in the field.

AUTOIMMUNITY REVIEWS is an esteemed journal in the field of immunology and allergy, published by Elsevier and located in the Netherlands. With a remarkable impact reflected in its Q1 category rankings for both Immunology and Allergy, this journal stands at the forefront of advancing research and knowledge in autoimmune diseases. Its Scopus rankings are particularly notable, placing it at #14 in the Immunology and Allergy category and #17 in the broader scope of Immunology and Microbiology, underscoring its influential role in the scientific community with a commendable 94th percentiles in both domains. Since its inception in 2002, AUTOIMMUNITY REVIEWS has provided a multidisciplinary platform for researchers and practitioners to share landmark studies, case reports, and reviews that propel the understanding of autoimmune disorders. Although it does not currently operate under an open-access model, the journal ensures rigorous peer review and high-quality publications, making it an essential resource for anyone looking to stay informed about the latest developments in autoimmune research.

JCR-Journal of Clinical Rheumatology, published by Lippincott Williams & Wilkins, is a premier outlet dedicated to the field of rheumatology, recognized for its contributions and relevance among medical journals. Boasting an impact factor reflective of its vital role in disseminating innovative research, it currently holds a Q2 category ranking in Medicine (miscellaneous) and a Q3 ranking in Rheumatology as of 2023. With its convergence years spanning from 1995 to 2024, the journal aims to foster the advancement of knowledge in clinical practices, therapeutic advances, and patient management strategies concerning rheumatic diseases. Researchers, professionals, and students can access a wealth of benchmark studies and peer-reviewed articles, enhancing their understanding and collaboration within this dynamic field. By bridging clinical insights with rigorous research, the JCR-Journal of Clinical Rheumatology remains an important resource for advancing the understanding of rheumatologic disorders and improving patient care.

Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders, published by SAGE PUBLICATIONS LTD, is an esteemed open-access journal dedicated to advancing knowledge in the field of rheumatology and related immunological disorders. Since its inception in 2008, the journal has provided a platform for researchers and clinicians from around the world to disseminate cutting-edge studies and insights into arthritis and musculoskeletal conditions. Based in New Zealand, this journal has maintained a commendable standing in academic circles, evidenced by its Q3 quartile rankings in both Immunology and Allergy and Rheumatology categories for 2023, alongside respectable Scopus rankings. The journal serves as a vital resource for healthcare professionals, researchers, and students, facilitating enhanced understanding and treatment of musculoskeletal disorders through high-quality research and peer-reviewed articles. With a focus on fostering interdisciplinary collaboration and innovation in the field, Clinical Medicine Insights-Arthritis and Musculoskeletal Disorders is essential reading for those committed to improving patient outcomes and advancing scientific knowledge.

Rheumatology International, published by Springer Heidelberg, is a prestigious journal that focuses on innovative research in the field of rheumatology and immunology. Established in 1981, this peer-reviewed journal has contributed significantly to advancing our understanding of autoimmune disorders, clinical approaches, and therapeutic interventions. It holds a commendable Q2 ranking in the categories of Immunology, Immunology and Allergy, and Rheumatology as of 2023, showcasing its influence and importance within these disciplines. With a robust Scopus ranking—positioned 14 out of 73 in Medicine Rheumatology—it caters to a diverse audience of researchers, clinicians, and students committed to improving patient care and treatment modalities. Although it does not currently offer open access options, the journal remains a vital resource for insights on contemporary challenges and breakthroughs in rheumatological research, published from its base in Heidelberg, Germany.

Immunity is a premier journal published by CELL PRESS that has positioned itself at the forefront of immunological research since its inception in 1994. With its ISSN 1074-7613 and E-ISSN 1097-4180, this prestigious journal is recognized for its significant contribution to the fields of Immunology, Allergy, and Infectious Diseases, consistently achieving a Q1 ranking in these categories as per 2023 metrics. The journal is highly esteemed within the academic community, holding impressive Scopus rankings—4th out of 344 in Infectious Diseases and 3rd in both Immunology and Immunology and Allergy—placing it in the 98th percentile. Although not an Open Access journal, it provides critical insights and research developments that empower researchers, healthcare professionals, and students alike. With a commitment to advancing scientific knowledge, Immunity is crucial for those interested in understanding immune responses and their implications for health and disease.

Rheumatology & Autoimmunity, published by WILEY, is an emerging academic journal that delves into the intricacies of rheumatological diseases and autoimmune disorders, providing a critical platform for researchers and practitioners within the field. With an ISSN of 2767-1410 and E-ISSN 2767-1429, the journal aims to disseminate cutting-edge research in both clinical and laboratory settings, enhancing knowledge and understanding among professionals and scholars. Although currently classified in Q4 for Immunology and Allergy, and Q3 for Internal Medicine and Rheumatology as of 2023, the journal is positioned for growth and greater visibility in the scientific community. The three-year publishing span from 2021 to 2024 signifies a commitment to addressing contemporary issues and fostering collaboration among various disciplines related to immunology. As an open access journal, it provides wide accessibility, ensuring that groundbreaking research is available to a broad audience. This journal is poised to become a vital resource for those dedicated to advancing the understanding and treatment of autoimmune conditions.